Canurta Naturals Launches Hemp Flavonoid Complex™, SOVEREIGN 2026 Sells Out, and New Scientific Paper Published
- Canurta
- May 6
- 2 min read
Canurta Naturals Launches Hemp Flavonoid Complex™ on Updated Website
Canurta Naturals has launched its updated website for natural ingredient customers and introduced Hemp Flavonoid Complex™, a proprietary concentration of cannflavin-rich flavonoids designed to support oxidative balance and two pathways associated with inflammation.
Standardized for verified levels of these rare hemp flavonoids, Hemp Flavonoid Complex™ represents a first-of-its-kind approach to hemp-derived ingredient innovation. Distinct from cannabinoids and more conventional polyphenols, it offers brands a differentiated, science-forward ingredient rooted in one of hemp’s rarest and most underdeveloped bioactives.
Hemp Flavonoid Complex™ is being developed for a range of applications, including standalone liquid products and custom formulations such as capsules, dissolving films, powder blends, topicals, and transdermal patches.
SOVEREIGN 2026 Reaches Capacity, Waitlist Now Open
As Canurta continues expanding its commercial and innovation platform, interest is also building around SOVEREIGN 2026, co-hosted with International Business University (IBU) and TrainingGround.AI.
The May 28 event in downtown Toronto has now reached full capacity ahead of Toronto Tech Week. The one-day flagship gathering will bring together founders, technologists, institutional leaders, and students to explore the intersection of human performance, decentralized finance, and artificial intelligence.
Positive Pre-Clinical Trial Application Meeting with Health Canada
Alongside commercial momentum, Canurta continues to advance its botanical drug development programs.
Canurta received positive feedback in its recent pre-Clinical Trial Application meeting with Health Canada for a new botanical extract under development. The meeting marks a constructive step in the regulatory process and supports continued planning as the program advances.
Akhtar Lab Paper Accepted in Journal of Cannabis Research
A new paper from the Akhtar Lab led by Canurta Scientific Advisor Tariq Akhtar, titled “Prenylated apigenin derivatives from Cannabis sativa L.: isolation, biosynthesis, and anti-inflammatory properties,” has been accepted in the Journal of Cannabis Research and is now available in early-access form.
The study identified two non-psychotropic prenylated flavonoids from Cannabis sativa and examined both how they are biosynthesized and how they may act against inflammation.
The paper also reports that these compounds showed strong inhibitory activity against a key pro-inflammatory pathway, supporting continued interest in their therapeutic potential.
Canurta Naturals to Accept Bitcoin Payments Through Square
As Canurta Naturals continues to expand its platform, the company also announced plans to accept bitcoin payments through Square and allocate a portion of sales into Canurta’s Bitcoin treasury strategy in support of the Satoshi Trials™.
The initiative is designed to connect consumer revenue with Canurta’s broader long-term mission, creating a practical link between commerce, treasury discipline, and future research and product development. Additional updates are expected as payment acceptance, treasury allocation, and product availability continue to roll out.
